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the 72-hour period, without significant differences between 4°C 
and RT storage (29% and 20% initial values, respectively). T- 
cell content remained stable at both temperatures and in blood 
and BM HPC grafts during 3 days storage. A marked decline in 
the number of viable type 2 dendritic cell progenitors (DC2p) 
was seen in the first 24 hours in blood HPC grafts during stor- 
age at both 4°C and RT (27% and 24% and of initial values, 
respectively), while content of DC2p in BM HPC grafts 
remained stable up to 48 hours (60% and 70% initial values at 
4°C and RT, respectively). Conclusions: Storage at 4°C did not 
impair the content of viable CD34+ cells or T-cells in blood or 
BM ItPC grafts, and was superior to storage at RT in preserv- 
ing the overall viability of blood HPC grafts. DC2p are particu- 
larly sensitive to storage, and prolonged transit times may 
impact the content of these immuno-regulatory cells in trans- 
plants. 
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OUTCOME OF PATIENTS TREATED WITH HIGH DOSE MELPHALAN 
WITH OR WITHOUT TBI FOLLOWED BY CD34 SELECTED STEM CELL 
RESCUE USING THE BAXTER ISOLEX 3001 
B'roun, E.R.; Sigmund, D.; Essell, J.; Tievne~, C. Jewish Hospital, 
Cincimmti, OH. 
We treated 24 patients with multiple myeloma with high dose 
melphalan +/- TBI using CD34 selection between 1/99 and 7/01. 
Patients were treated as part of initial therapy following 4 cycles of 
VAD in most cases. Mobilization was with either VP16/ 
cyclophosphamide (5) or cyclophosphamide (19) followed by G- 
CSF. Patients then underwent 20L apheresis on a COBE Spectra 
with a collection goal of 6.5 x 106 CD34+ cells/kg. CD34 selection 
with the BAXTER Isolex 300i was carried out on the pheresis 
product with 1.5 x 106 CD34+cells/kg stored as backmp. Patients 
underwent a median of 2 phereses (range 1-6) with a mean collec- 
tion of 24.1 x 10 6CD34+ cells/kg (range 6.9-57.8). Following 
selection, a mean of 10.4 x 106 CD34+ cells/kg were infused at 
time of transplant. Post infusion recovery of WBC to an ANC 
>500/uL occurred in a mean of 26.9d (range 13-7 l d) and platelets 
to >20, 000/uL at 79.3d (range 15-360d). 4 patients expired prior 
to recovery of platelets and one remains platelet ransfusion 
dependent 3 years post transplant. There was one early death due 
to aspiration pneumonia. Overall 10 pts have expired, cause of
death: progressive disease 6, pneumonia 2, sepsis 2. The remain- 
ing 14 pts are alive, 3 in relapse and 11 (46%) in remission. Nine 
patients have relapsed (38%). Mean follow-up for the entire 
group is 18.4 mos. For the 11 pts in remission the median time 
frmn transplant is 18 mos (14-41 mos). CD34 selection led to pro 
longed recovery of granulocytes and platelets. Longer follow-up is 
needed to assess the durability of the remissions. 
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ENGRAFTMENT AND PRODUCTION OF MESENCHYMAL COLONY 
FORMING CELLS (M-CFC) IN VITRO 
La Russa, ~:F.; Lee, M.; Price, S.; Sarah, H.; Mille1", A.; Rozm~s, M.; 
~Veiner, R. TULANE UNIVERSITY CANCER CENTER, NEW 
ORLEANS, L4. 
A 2-stage stromal cell culture system that supports production of 
early hematopoietic progenitor cells (LTCIC, CFU-BLAST) was 
evaluated tbr mesenchymal progenitor cells, M-CFC. Stage-1 was 
initiated by culturing female bone marrow low density" mononu- 
clear cells (LDMNC) for 2 weeks. At day 0, 2-week old female 
recipient stromal colonies were lethally irradiated (25Gy) to elimi- 
nate endogenous M-CFC(XX) and then seeded with 2.5X10 ~ 
LDMNC from male-donor bone marrow containing only 27+_3 
M-CFC(XY). Engraftment and subsequent production of male 
donor-derived M-CFC (XY) activity was measured weekly by sec- 
ondary plating of both non-adherent and adherent cell fractions 
derived from female-recipient stromal colonies that were initially 
seeded with male donor bone marrow LDMNC. Fluorescence in
situ-hybridization (FISH) with DNA probes DXZI from the X- 
chromosome centromere region and the DYZI from the Yql2 
region was performed on representative s condary M-CFC 
derived stromal colonies at each week. At week-1 there was >7X 
expansion of M-CFC(XY) activity in both adherent and non- 
adherent stromal cell fractions as compared to the original 27+3 
M-CFC(XW) added at day 0. Most of the M-CFC(XY) activity 
localized within the female recipient adherent stromal cell fraction 
contained 187+-17 M-CFC(XY)/plate and formed individual stro- 
mal colonies with surface area r nge: 4rome; <16 mm 2. In addition, 
there were 20+2 M-CFC(XY)/plate, that were more proliferative 
and formed larger colonies with surface area range: >16 ram-'; < 30 
mm~, and 10+-2 M-CFC(X~/plate with the highest proliferative 
potential forming colonies with surface area: >30 mm 2. At week-2, 
ahnost all of the M-CFC(XY) remained in direct-contact with the 
female recipient adherent stromal cell fraction and continued to
further expand to 490+50 M-CFC(XY)/plate. The plating effi- 
ciency of mesenchymal progenitor cells at 3-weeks was >90% with 
a yield of 1, 150+-150 M-CFC (XY) / plate, but their proliferative 
index was reduced to form smaller stromal ceil colonies with sur- 
face area 4mm-'; <16 nun 2, and 13,600+-770 stromal cell clusters 
(XY)/plate. These studies show" that lethally irradiated female 
recipient mesenchymal/stromal cell colonies upport the engraft- 
ment of pre-clonogenic mesenchymal stenrcells. 
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FLOW CYTOMETRIC ANALYSIS OF CELLULAR DIFFERENTIATION 
ARREST IN MYELODYSPLASTIC SYNDROME 
S,beJw~an, M.; Dicke, K.; Palmer, D. Stem Cell Lab, A'dington Cance'~" 
Center, Arlington, T2~ 
CD33 has been shown to be a marker for cellular immaturity at 
the promyelocyte l vel. One of the hematological findings in 
myelodysplastic syndrome (MDS) is cellular differentiation (mare- 
ration) arrest. The purpose of this study was to determine the 
diagnostic utility of flow cytometry in confirming the clinical find 
ings in MDS. Our study analyzed the percentage of CD33+ and 
CD 33 +/CD 11 c+ cells by flow cytometry in 18 patients clinically 
diagnosed with MDS. Controls consisted of 30 patients who were 
hematologically normal. Normal ranges for CD33+ and 
CD33+/CD11c+ were 19-41% and 58-80%, respectively. All 18 
MDS patients were found to have a percentage of CD33+ cells in 
excess of 41% (43-68%) and a percentage of CD33+/CDllc+ 
cells less than 58% (31-56%), clearly demonstrating anaccumula- 
tion of ceils at the promyelocyte l vel at the expense of mature 
cells, demonstrating maturation arrest. We also found a slight 
increase in CD34+/CD33+ cells (from 0.5% to 0.73 %), therefore 
a prelude for excess blast cells and the possible transformation f 
MDS into acute myelocytic leukemia (AML). We conclude that 
flow cytometry is a promising tool in assisting the clinician in 
diagnosing MDS and its progression. 
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MOBILIZATION OF PERIPHERAL BLOOD PROGENITOR CELLS (PBPC) 
WITH COMBINATION OF CYTORINES IN AUTOLOGOUS AND ALLO- 
GI:NEIC PEDIATRIC TRANSPLANT 
Guev~'a, J.A.; Mm'tinez, C.A.; Barrios, N.J. Pediatrics, Univer,'ity of 
Puel"to Rico Sc,%ol of MedMne, San J.an, Pue'~to Rico. 
Background:Clinical trials to mobilize PBPC for antologous 
and allogeneic harvesting prior to high dose chemotherapy / 
radiotherapy include chemotherapy, eytokines, or chemotherapy 
combined with cytokines. PBPC mobilized by G CSF or GM- 
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CSF reduces the hematological toxicity and supportive care 
requirements in recipients of autologous and allogeneic trans- 
plants. In our staldy we combined G-CSF and GM-CSF to mobi- 
lize PBPC for transplantation. Method: A total of 21 subjects par- 
ticipated in the study. Seven patients had neuroblastoma stage IV; 
6 had stage IV Hodgkins lymphoma; 2 had second remission acute 
myeloid leukemia; 2 had third remission acute lymphoblastic 
leukemia; 1 had second relapsed rhabdomyosarcoma, and 1 with 
myelodisplastic syndrome. There were 2 normal donor children. 
All were under 18 years old. All the patients were mobilized with 
G-CSF & GM-CSF, 10ug/kg/d x 5 days each, followed by PBPC 
harvesting until a threshold of 2.0xI06/Kg CD34+ cells was 
obtained. A total of 11 autologous and 2 allogeneic PBPC trans- 
plants were performed. Results: Data on PBPC 24, 48, 72, and 
96hrs after the fifth dose of cytokines are shown in the below 
table: Six patients required 2 apheresis, 7 required 3, and 7 
required 4 apheresis to achieve our goal. For the 11 PBPC autolo 
gous transplant patients, the median days to get an 
ANC>500/mm 3 was 9.8 days; 9.5 days for the allogeneic. Median 
days to platelets engraftment was 11.5 days for the autologous 
PBPC; 12.5 for the allogeneic. None of the subjects experience 
bone pain, headache, flu like side effects or a documented o 
proven infection. Conclusions: The combination of G-CSF & 
GM-CSF (10ug/kg/day x 5 days) is well tolerated. It contrived a
clinical reduction in the degree and duration of severe neutropenia 
and thrombocytopenia in both allogeneic/autologous transplants. 
It seems to be cost effective and adequate to mobilize more than 
an average numbers of PBPC(2-3 apheresis) to perform allogene- 
ic/autologous hematopoietic ransplant in pediatric population. 
Parameter 24 48 72 96 Total 
Mean #CD34+x10exp6/kg 4.47hrs 3.87hrs 2.12hrs 1.20hrs 11,65 
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CLINICAL AND QUALITY OF LIFE MONITORING IN MULTIPLE SCLE- 
ROSIS PATIENTS UNDERGOING HIGH DOSE CHEMOTHERAPY AND 
AUTOLOGOUS STEM CELL TRANSPLANTATION 
Novik, A.AJ; IoTmva, T.I/; Lisz~kov, I.A.:; Kulag~l, A.A.:; Malysheva, 
O.A.e; Bisag~, G.N.~; 3/lelTlicheTzko, U.I'~1; Chelombit, L.f'U; Kish- 
tovich, A.I.~I; Osipova, N.EJ 1. Rassimz Cboperative Group of High 
Dose ChemotheT:apy iJ~ AuroimmuT~e Diseases, St.Petersbm'g, Rnssia~ 
Fe&ratiom 2. Russian Coopelvltive Group of High Dose Chemother~ W 
ilz ~'tlttoi77177zlt't~e Diseases, Novosibh's/e, Rltsskl~7 Federatiol~. 
High dose chemotherapy (HDCT) with autologous tem cell 
transplantation (ASCT) is a new treatment strategy for patients 
with multiple sclerosis (MS). Quality of life (QoL) is increas- 
ingly used as a treatuaent outcome along with traditional clini- 
cal outcomes. Monitoring of clinical and QoL outcomes of 
HDCT and ASCT in MS patients is worthwhile. The aim was 
to provide monitoring of clinical outcomes and QoL parame- 
ters in MS patients before and at different ime-points after 
ASCT. Seven patients with MS, who underwent HDCT and 
ASCT within Russian Cooperative Group of High Dose 
Chemotherapy in Autoiminune Diseases, were enrolled in the 
study. All the patients previously underwent conventional 
treatment. The transplantations were performed in accordance 
with EBMT protocols. MRI was carried out before APSCT 
and repeated every 6 months. QoL was assessed by Russian 
versions of QoL questionnaires: FACT-BMT - specific for 
patients with BMT, FAMS - specific for MS patients. QoL and 
EDSS evaluation were provided at baseline, at discharge, and at 
3, 6, 8, 12 months and eve W 6 months following ASCT. Fol- 
low-up period varied from 6 to 36 months (one patient - 6 
months, three patients -18 months, two patients - 24 months, 
one patient 36 months). Stabilization of the disease was 
achieved in six cases: in four patients no new lesions on MRI 
were observed, in two patients a decrease in the number of 
lesions took place. In one patient one new lesion appeared 1.5 
years after APSCT. Comparison of EDSS before ASCT and at 
follow-up revealed its decrease in 6 patients; in one patient it 
remained the same and in the patient with disease progression 
EDSS increased (from 6.5 to 7.0). Distinct QoL improvement 
was observed in all the patients with disease stabilization at the 
end of follow-up. QoL improvement on the majority of scales 
was achieved within 3 months after ASCT as compared to 
baseline with a tendency to further improvement a late follow- 
up. Definite QoL improvement was documented at one year 
after ASCT and remained stable throughout the later follow- 
up in the patients with long-term follow-up. HDCT and 
ASCT in patients with MS resulted in disease stabilization in 
six out of seven patients under observation. Along with clinical 
improvement distinct increase of QoL parameters in MS 
patients took place. 
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QUALITY OF LIFE IN PATIENTS WITH CHRONIC GRAFT VS HOST DIS- 
EASE: A QUALITY PROCESS IMPROVEMENT IN BLOOD AND MAR- 
ROW TRANSPLANTATION 
Neumam~, if.£.; Hsa, Y.; Tallarigo, ft.; ChampliJ~, R.; Coltriel, D. 
Blood and Marrow 7)'a~splmmttion, U iversity of Texas MD Anderson 
CmTcer CenTre1", HoustoT~, TX. 
Chronic Graft vs. Host Disease (cGVHD) occurs in approxi- 
mately 50% of post allogeneic blood and marrow transplantation 
(BMT) patients. The effects can be devastating to patients, who 
have survived this aggressive treatment regimen to cure or control 
their malignancies. At our comprehensive cancer center, the 
GVHD clinic MD, APN and/or PA evaluate patients with 
cGVHD referred by other BMT or community physicians. The 
clinic uses a multidisciplinary approach to provide patients com- 
prehensive assessment and treatment for the physical and psy- 
chosocial issues. During the initial assessment the patients com- 
plete the FACT-BMT (Functional Assessment of Cancer 
Therapy) and the MDASI (MD Anderson Symptom Inventory) to 
help identify quality of life (QOL) issues. The FACT-BMT is a 
50-item (0-4 scale) instrument measuring QOL with subscales 
including physical, social/family, emotional and functional wel
being as well as items, addressing BMT related issues (infertility, 
eyesight, memory, regret about BMT, cost, family hardship). 
Higher scores indicate improved the QOL. The tool developed by 
Cella has demonstrated reliability and validity. The MDASI is a 
13-iteln (0-10 scale) tool that measures ymptoms experienced. 
The outcomes data on 36 cGVHD patients who were 6 months to 
12 years post BMT indicated the following results: patients expe- 
rienced the greatest alterations in the functional, physical, and 
emotional domains. The majority (97%) experienced problems 
with skin, blurred vision (73%), hardship on family (71%), memo- 
I T (69%) and financial burden (67%). The data from the MDASI 
indicated the 5 most frequently reported symptoms to be: fatigue 
(73%), sleep disturbance (70%), sadness (70%), drowsiness (67%), 
and dry mouth (64%). With information from the QOL tools and 
comprehensive physical examination, patient referrals were expe- 
dited. Improvement in patients QOL with sequential dministra- 
tion of the tools demonstrates the importance of this GVHD mul- 
tidisciplinary clinic approach. 
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PERFORMANCE OF YOUNG LONG TERM SURVIVORS AFTER ALLO- 
GENEIC STEM CELL TRANSPLANTATION (SCT) 
Laltl-sen, H.B.; ffacobse~, N.; Heilmam~, C. Haelnatologic CliMe, 
B3/iT-mzit, Rigshospitalet, CopenhdgeJ~, Demnavk. 
Purpose: To examine overall performance of adolescents and 
young adults who have survived long" term after allo-SCT. Perfor- 
mance was estimated by means of Lansky and Karnofsk T scores. 
Patients & methods: Patients were all transplanted at the same 
BMT unit between1987 and 1997. Age at transplant was 10 to 30 
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